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Abstract
The Policy Research Working Paper Series disseminates the findings of work in progress to encourage the exchange of ideas about development 
issues. An objective of the series is to get the findings out quickly, even if the presentations are less than fully polished. The papers carry the 
names of the authors and should be cited accordingly. The findings, interpretations, and conclusions expressed in this paper are entirely those 
of the authors. They do not necessarily represent the views of the International Bank for Reconstruction and Development/World Bank and 
its affiliated organizations, or those of the Executive Directors of the World Bank or the governments they represent.
Policy ReseaRch WoRking PaPeR 4295
Tuberculosis is the most important infectious cause of 
adult deaths after HIV/AIDS in low- and middle-income 
countries. This paper evaluates the economic benefits 
of extending the World Health Organization’s DOTS 
Strategy (a multi-component approach that includes 
directly observed treatment, short course chemotherapy 
and several other components) as proposed in the 
Global Plan to Stop TB, 2006-2015.  The authors use 
a model-based approach that combines epidemiological 
projections of averted mortality and economic 
benefits measured using value of statistical life for the 
Sub-Saharan Africa region and the 22 high-burden, 
tuberculosis-endemic countries in the world. 
   The analysis finds that the economic benefits between 
2006 and 2015 of sustaining DOTS at current levels 
relative to having no DOTS coverage are significantly 
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greater than the costs in the 22 high-burden, 
tuberculosis-endemic countries and the Africa region. 
The marginal benefits of implementing the Global Plan 
to Stop TB relative to a no-DOTS scenario exceed the 
marginal costs by a factor of 15 in the 22 high-burden 
endemic countries, a factor of 9 (95% CI, 8-9) in the 
Africa region, and a factor of 9 (95% CI, 9-10) in the 
nine high-burden African countries. Uncertainty analysis 
shows that benefit-cost ratios of the Global Plan strategy 
relative to sustained DOTS were unambiguously greater 
than one in all nine high-burden countries in Africa 
and in Afghanistan, Pakistan, and Russia. Although 
HIV curtails the effect of the tuberculosis programs by 
lowering the life expectancy of those receiving treatment, 
the benefits of the Global Plan are greatest in African 
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   1. Introduction 
Adult mortality has a significant effect on national economies, both through the direct 
loss of productivity among those of working age and by altering fertility, incentives for 
risk-taking behavior, and investment in human and physical capital. Tuberculosis (TB) is 
the most important cause of adult death due to infectious disease after HIV/AIDS. 
Roughly 8.8 million new TB cases and 1.7 million TB-related deaths were reported in 
2003 (Corbett, Watt et al. 2003), including 229,000 deaths of individuals who also were 
infected with HIV/AIDS. Almost all of those who died from the disease lived in low- and 
middle-income countries (Lopez, Mathers et al. 2006) and most were between age 15 and 
49 (Styblo and Rouillon 1991). Table 1 provides estimates of TB-related deaths from the 
World Health Organization (WHO) in the 22 countries with the highest burden of TB in 
2004. 
TB places an extraordinary burden on those afflicted by the disease, their families, and 
communities and on government budgets. The greatest burden of TB falls on productive 
adults who, once infected, are weakened and often unable to work. The burden of taking 
care of sick individuals usually falls to other family members and, in addition to putting 
them at greater risk of infection, can lower their productivity. Besides loss of 
productivity, the cost of treating TB also can be significant. Mean household spending on 
TB can account for as much as 8–20 percent of annual household income, varying by 
region (Russell 2004). Children also are affected. Each year, a significant proportion of 
children from families in India in which the primary breadwinner has TB are forced to 
drop out of school or seek employment (Rajeswari, Balasubramanian et al. 1999). 
However, the most devastating impact of TB is death; without treatment, two-thirds of 
smear-positive cases die within five to eight years, with most dying within 18 months of 
being infected (Styblo and Rouillon 1991).  
 
Impact of adult mortality on economic growth  
Adult deaths place an especially high economic burden on societies. The loss of 
working-age adults represents a loss of human capital and has a profound effect on 
household economic well being. A cross-sectional study of the effects of adult mortality 
1   on small farmers engaged in cotton and maize production in Zambia found that an adult 
death resulted in a decline in crop output of roughly 15 percent (Larson, Hamazakaza et 
al. 2004). Yamano and Jayne (2004) find that an adult death and associated funeral 
expenses reduce purchases of agricultural inputs, such as farm animals and fertilizer, and 
jeopardize agricultural production. In addition, these studies find that the effect of adult 
mortality is greatest on households that were relatively poor to begin with, in part 
because they are less able to cope with unanticipated shocks (Beegle 2005). Other studies 
have shown that adult mortality has a deterrent effect on the acquisition of human 
capital.
2 Individuals may be less willing to get a higher education or make investments 
that pay off in the longer term, especially those that cannot be transferred to future 
generations in the same way as financial investments, if there is a greater risk that they 
may not be around to enjoy the returns of that investment. 
There is a large literature on the economy-wide impact of adult deaths, mostly in the 
context of understanding the impact of the sharp decline in mortality rates that 
characterized much of the 20th century (Bhargava, Jamison et al. 2001; Bloom, Canning 
et al. 2004). Boucekkine finds that more than two-thirds of pre-industrial European 
economic growth between 1700 and 1820 was accounted for by reductions in adult 
mortality (Boucekkine, Croix et al. 2003).  Researchers have tried to understand and 
estimate the causal pathways by which health, more specifically adult mortality, affects 
growth. Greater adult mortality implies a lower rate of return to human capital 
investments, which in turn is a determinant of economic growth. One study in which 
individuals make optimal schooling investment choices in the face of a constant 
probability of death found a 1% increase in schooling for each percentage decline in 
mortality (Kalemli-Ozcan, Ryder et al. 2000).  
Another key route by which mortality affects growth is through fertility. Exogenous 
mortality declines have been linked to a lower precautionary demand for children and 
greater investment in children’s human capital, both of which have a beneficial impact on 
growth of per capita GDP (Kalemli-Ozcan 2002). Kalemli-Ozcan also finds evidence of 
                                                 
2 See Kalemli-Ozcan et al. (2000) for instance, who show that lower mortality increases individual time 
horizons and hence the incentive to invest in human capital.  
2   increased fertility and lowered school enrollment between 1985 and 2000 in many 
African countries, as a consequence of HIV/AIDS deaths (Kalemli-Ozcan 2005).  
The links between mortality and economic wellbeing are not always straightforward. 
Becker et al show that life expectancies worldwide converged between 1960 to 1990 
while incomes diverged over the same period, indicating that life expectancies were 
probably not a significant predictor of economic growth (Becker, Philipson et al. 2003). 
In their study of the relative importance of contracting and property rights institutions, 
Acemoglu and Johnson find a negligible effect of life expectancy on per capita GDP 
(Acemoglu and Johnson 2006).  Finally, Young used a calibrated simulation model to 
show that HIV/AIDS could improve economic prosperity by lowering fertility (Young 
2005). This comes about directly because of a lower willingness to engage in unprotected 
sex, and indirectly by increasing labor scarcity and driving up women’s wage rates. The 
effect of these two mechanisms outweighs the adverse impact of the disease on 
education. 
Recent work has tried to provide a more consistent estimate of the different channels – 
increased risky behavior, lower investment and higher fertility – by which adult mortality 
affects economic growth (Lorentzen, McMillan et al. 2005). Estimates of the growth 
effect of adult mortality ranges from 0.8 to 1.4 percentage points associated with a one 
standard deviation increase in mortality, which implies that adult mortality could explain 
the growth shortfall in Africa between 1960 and 2000. An important caveat to these 
estimates is that they do not separately identify the effect of poor health from those of a 
shorter planning horizon imposed by higher mortality rates, but they provide a carefully 
estimated set of estimates of the impact of mortality on growth. 
In this paper, we estimate the mortality-related costs of TB in Sub-Saharan Africa and 
the 22 countries with the highest burden of TB using a value of statistical life (VSL) -
based, full-income growth approach. Our goal is two-fold: first, to assess the order of 
magnitude of the economic impact of TB; and second, to evaluate the benefits and 
benefit-cost ratios of DOTS programs (under two scenarios) to reduce TB cases and 
deaths. We ignore the morbidity effects of TB because premature death, rather than 
morbidity, is responsible for more than 80 percent of the disability-adjusted life years lost 
3   to TB (Dye 2006). Also, a significant proportion of the TB-afflicted population may be 
unemployed prior to developing the disease (Rajeswari, Balasubramanian et al. 1999) and 
labor supply may be fairly elastic; therefore, morbidity-related productivity costs are 
likely to be small relative to the economic burden of deaths caused by TB. 
 
2.  TB, DOTS and Global Strategies 
 
Current Situation 
The Millennium Development Goals (MDG) for TB call for halting and beginning to 
reverse the incidence of TB by 2015, while the Stop TB Partnership goals call for halving 
prevalence and death rates by 2015 relative to 1990 rates. These goals are thought to be 
achievable if at least 70 percent of new infectious (smear-positive) cases worldwide are 
detected and at least 85 percent of those cases are treated successfully.  
Much progress has been made toward reaching these targets, mainly facilitated by 
tremendous improvements in case detection and treatment. The case-detection rate 
through the introduction and expansion of the WHO’s DOTS Strategy (a multi-
component approach that includes directly observed treatment, short course 
chemotherapy and several other components) increased from 11 percent globally in 1995 
to 53 percent in 2004. More than 21 million TB patients were treated in DOTS programs 
between 1994 and 2004 (WHO 2006). However, achieving the MDGs will be challenging 
given the rapid increase in the incidence of TB in Sub-Saharan Africa and Eastern Europe 
during the 1990s.  
In Sub-Saharan Africa, the number of new TB cases was rising at 3–5 percent per year 
despite the DOTS program until around 2005, and efforts to control the disease are 
challenged by the problem of co-infection with HIV. In 2003, 33 percent of new TB 
cases in this region were in adults also infected with HIV, leaving approximately12 
million adults co-infected with TB and HIV.  
In Eastern Europe, economic factors, such as increasing levels of unemployment and 
deteriorating public health systems, are responsible for the increasing number of TB 
4   cases. Multi-drug-resistant TB (MDR-TB) in particular poses a significant challenge 
(Kazionny, Wells et al. 2001); TB patients in Eastern Europe and Central Asia are 10 
times more likely to have MDR-TB than in other regions of the world, and 5.5 percent of 
new cases are multi-drug resistant (Dye, Espinal et al. 2002). 
 
Evidence on the effect of treatment (DOTS programs) on TB incidence, prevalence, 
and mortality 
Before drawing a link between DOTS and declines in TB mortality, we review the 
evidence on the effectiveness of DOTS in controlling TB. Although TB declined before 
the introduction of drug treatment in many parts of the world, the decline has been 
accelerated since the 1950s by good chemotherapy programs, as seen in Western Europe 
(Styblo 1991), part of Northern Africa, and Latin America (e.g., Chile, Cuba, Uruguay). 
Data from Morocco and Peru provide two recent examples of the effect of treatment on 
transmission and incidence. Between 1994 and 2000, the incidence of pulmonary TB 
among Moroccan children 0–4 years of age fell at more than 10 percent per year, 
suggesting that the risk of infection was falling at least as quickly (Ministry of Health 
Morocco, unpublished data). The average age of TB cases also has been increasing for 
more than 20 years in Morocco as a consequence of falling transmission rates. The 
overall reduction in the incidence rate of pulmonary TB over the past decade was 4 
percent per year. In Peru, DOTS was launched in 1991, and high rates of case detection 
and cure have pushed down the incidence rate of pulmonary TB by 6 percent per year 
(Suarez, Watt et al. 2001).  
Some countries have measured the reduction in TB prevalence over time in the 
presence of good chemotherapy programs, though the reduction cannot always be 
attributed entirely to drug treatment. The Republic of Korea carried out seven surveys at 
five-year intervals between 1965 and 1995, during which time the prevalence of 
bacteriologically positive cases (smear- and/or culture-positive) of disease fell from 940 
per 100,000 to 219 per 100,000 (Hong, Kim et al. 1998). Two prevalence surveys done in 
China in 1990 and 2000 showed a 32 percent (95% CI, 5%–68%) reduction in the 
prevalence per capita of smear-positive TB in DOTS areas, as compared with a negligible 
5   change in prevalence in other parts of the country (China Tuberculosis Control 
Collaboration 2004). A national survey in Indonesia in 2004 found that the prevalence of 
smear-positive TB had fallen by a factor of three since a set of regional surveys were 
carried out between 1979 and 1982 (Aditama 1991; Soemantri, Senewe et al. in press). 
Most of this reduction may be due to drug treatment (especially the widespread 
availability of rifampicin since the early 1980s), though not to treatment administered by 
the recently expanded, higher-quality DOTS program. 
Some investigations of the effect of DOTS programs have shown that after several 
years of implementation, TB incidence appears not to be falling as expected, as judged 
from nationally aggregated data. Vietnam apparently exceeded the targets for case 
detection and treatment success since 1997, and yet the case-notification rate remained 
approximately stable over that period (Huong, Duong et al. 2006). Closer inspection of 
surveillance data shows that while case-notification rates are falling among adults aged 
35–64 years (especially women), they are increasing among 15–24 year-olds (especially 
men) (World Health Organization 2007). The program of drug treatment, therefore, does 
appear to be having the anticipated effect on transmission in one segment of the 
population─ middle-aged women. The increase in TB incidence among young adults is 
likely to be due, in part, to HIV co-infection.  
The southern Indian states of Kerala and Tamil Nadu, among others, showed an 
increase in the average age of TB cases over the past decade, which may reflect falling 
transmission, corresponding with the expansion of the revised national TB control 
program (RNTCP). The RNTCP has yet to demonstrate that TB incidence is falling on a 
large geographical scale (e.g., across a whole state) as a result of its activities, though 
transmission and prevalence have been reduced in the model DOTS project in the 
Tiruvallur District in Tamil Nadu (Gopi, Subramani et al. 2006; Subramani, Santha et al. 
2006). 
Although it is not straightforward to evaluate the effect of DOTS on transmission 
because large-scale public health programs are not carried out as controlled experiments 
and because major changes in TB incidence happen over decades, it is widely believed 
that high-quality drug treatment, properly administered under DOTS, can markedly 
6   reduce the TB case-fatality rate and already has saved the lives of millions of TB patients 
(Dye, Fengzeng et al. 2000; Suarez, Watt et al. 2001; Khatri and Frieden 2002).  
 
Stop TB Strategy and the Global Plan to Stop TB (2006-15) 
Since the launch of the DOTS strategy during the 1990s, a series of specific, emerging 
problems in TB epidemiology and control have demanded specific solutions. These 
include M. tuberculosis and HIV co-infection, drug resistance, the poor quality of 
treatment in the private sector, and the need to evaluate the epidemiological effect of TB 
control (not simply the implementation of DOTS). For this reason, DOTS has been 
extended as the Stop TB Strategy (Raviglione and Uplekar 2006; World Health 
Organization 2007). The blueprint for implementing the Stop TB Strategy over the next 
decade is the Global Plan to Stop TB (2006–15) (Stop TB Partnership and World Health 
Organization 2006). The plan sets out and compares three scenarios (also see Table 2 and 
Figures 1 and 2): 
Scenario 1: No DOTS. This assumes that the DOTS strategy was never introduced in 
any region, so chemotherapy would continue as it was pre-DOTS, with variable rates of 
case detection and typically lower rates of cure. This gives a baseline against which to 
compare gains that already have been made and that might be made in the future. 
Scenario 2: Sustained DOTS. Case-detection and treatment success rates increase 
until 2005 and then remain steady until 2015. Approximately 50 million patients would 
be treated under DOTS between 2006 and 2015, as compared with more than 20 million 
in the previous decade, 1996–2005.  
Scenario 3: Global Plan Strategy or Enhanced DOTS. Case-detection and treatment 
success rates continue to increase beyond 2005, up to 2015. As in scenario 2, roughly 50 
million patients would be treated between 2006 and 2015 (a higher proportion of patients 
treated sooner means that, as a result of reduced transmission, there are fewer patients 
later). To reach high rates of case detection and cure requires various additions to the 
basic DOTS strategy, including community-based care, a syndromic approach to 
diagnosing and treating TB among other respiratory conditions, and improved 
collaboration between public and private health sectors. To improve the management of 
7   drug-resistant disease, more patients will be given drug-sensitivity tests, and 
approximately 800,000 MDR-TB patients will be treated with regimens including 
second-line drugs. HIV testing and counseling will be provided to 27 million TB patients, 
and antiretroviral therapy and co-trimoxazole preventive therapy will be offered to 3.2 
million. Approximately 200 million people infected with HIV will be screened for TB, 
and 24 million will be offered isoniazid preventive therapy. 
The scenarios do not account for the implementation of new technology (drugs, 




In this paper we evaluate the economic benefits of extending the World Health 
Organization’s DOTS strategy (a multi-component approach that includes directly 
observed treatment, short course chemotherapy and several other components) using a 
model that combines epidemiological projections of averted mortality and economic 
benefits measured using a value of statistical life (VSL) approach. Other methodological 
approaches to this evaluation and the rationale for selecting the VSL-based approach are 
described in another paper that preceded these analyses (Laxminarayan 2006).  Briefly 
these include cost-of-illness approaches using the human capital method or stated 
preference; sectoral approaches estimating the effect of disease on a particular sector of 
the economy (such as of malaria on tourism); and macroeconomic estimates based on 
models or cross-country growth regressions. These other approaches may lead to 
different estimates of economic benefits.  
Here we describe the full-income approach to estimating the economic burden of a 
baseline scenario of No DOTS and then evaluate the economic benefit of moving to the 
Sustained DOTS and the Global Plan (enhanced DOTS) scenarios described earlier. An 
important methodological challenge is posed by the large number of TB-infected people 
worldwide, especially in Sub-Saharan Africa, who also are co-infected with HIV. Since 
there is no easy way to disentangle the effects of the two diseases, two sets of estimates 
are presented for TB-related deaths, one excluding HIV co-infection and another 
8   including HIV co-infection. Estimates excluding the benefits of lowering TB–HIV co-
infections may underestimate the benefits of DOTS coverage but avoid the risk of 
double-counting the costs of TB and HIV. To a large extent, the benefits of TB-control 
programs depend on the availability of antiretroviral treatments, and the benefits of TB 
control and treatment are likely to be greatest in countries where the life expectancy of 
co-infected patients is not curtailed by AIDS. 
 
Incorporating health gains in GDP measures: full-income approach 
GDP measures are the most widely used measures of economic activity in countries, 
but they have well-known, serious shortcomings, such as not measuring nonmarket goods 
(health, for instance) and home production. Two countries could have the same per capita 
GDP, but life in one country could be long and healthy while it is short and unhealthy in 
the other. GDP calculations fail to take account of health because they are based on what 
an economy produces rather than on the aggregate utility (or happiness) of the country’s 
population.
3  
A growing literature on the economic value of health improvements has focused on 
expanding the idea of GDP to include improvements in health (Usher 1973; Nordhaus 
2002; Becker, Philipson et al. 2003; Murphy and Topel 2005).
4 This concept, known as 
full-income GDP, incorporates both annual income and the number of years over which 
this income is enjoyed. In short, full-income approaches impute the value of increased 
life expectancy on economic well-being using revealed-preference approaches to value 
each year of longer life. Longevity gains can be quantitatively important when measuring 
welfare. Becker and colleagues find that when longevity gains are taken into 
consideration, average yearly “full income” grew 4.1 percent between 1960 and 2000 for 
the poorest 50 percent of countries, of which 1.7 percentage points were due to health 
(Becker, Philipson et al. 2003). The implication is that much of the welfare improvement 
                                                 
3 GDP measures do take into account what a country spends on health but do not measure or value the 
output of the health sector. 
4 A recent WHO report incorporated these methods to measure the economic effect of chronic disease 
(WHO 2005) and determine changes in full-income attributable to reductions in chronic disease in regions 
where there have been significant improvements. 
9   in poorer countries over the past few decades has come in the form of improved health 
and that the economic contribution of these longevity increases is important. 
A formal approach used to calculate the economic value of increased longevity is 
based on translating increases in survival rates into incremental annual incomes required 
to yield the same utility level as with the original survival probability (Becker, Philipson 
et al. 2003) and is presented in Annex 1 in Laxminarayan (2006). 
 
Valuing improvements in health 
 
To value the improvement in health status represented by TB-control programs, an 
appropriate “price” to place on health must be found. Although most would agree that 
saving someone from certain death is a moral imperative that a value cannot be placed 
on, preventing every single probabilistic death is unaffordable and infeasible, even in the 
wealthiest countries in the world. The term "value of a statistical life" (VSL) is used 
widely in economics and regulation to denote not the value placed on a particular life but 
on the public-health measures that can reduce the statistically expected number of deaths 
by one. 
Three principal approaches are used to evaluate VSL or willingness to pay for 
reducing risks to life. The most common approach is based on wage-risk tradeoffs, 
whereby workers are paid risk premiums to accept jobs with a higher risk of death or 
injury.  The VSL is defined as the willingness to pay for a risk reduction divided by the 
risk reduction. Therefore, if lifetime wages for a high-rise construction worker with a 
1/1,000 greater probability of death on the job are $500 more than for a worker with a 
similar job but with a lower risk of death, VSL is calculated as $500,000. VSLs are 
estimated through revealed-preference approaches (as distinct from stated-preference 
methods where respondents are asked how much they would hypothetically pay for lower 
risk of death), such as hedonic wage studies that use labor-market data to estimate the 
effect of morbidity and mortality risk on wage differences between occupations with 
differing levels of risk, after controlling for other variables that would explain wages. For 
example, all else being equal, a construction worker employed on a high-rise building 
10   will have to be paid more than one working on a single-storey building to compensate 
him for a the greater probability of dying on the job.   
A second approach is based on observing the behavior of consumers to see how much 
they are willing to pay in exchange for safety features, such as automobile seat belts or 
safer vehicles, to lower the risk of death. The third approach differs from the first two 
approaches, which are based on observing actual behavior, and instead is based on survey 
responses to hypothetical questions about the willingness to pay for a lower risk of death 
or disability. There are a number of problems with the stated-preference approach that 
could introduce bias in VSL estimates, but these methods have improved substantially 
over the years. The VSL estimates used in our study are based on the first approach. 
There have been some conceptual and implementation-related critiques of VSL. [For a 
fuller discussion, see a working paper by Grüne-Yanoff 
(http://www.infra.kth.se/~gryne/VLS061120.pdf). Arguments against VSL relate to 
specific measurement practices and particular contexts of applications and do not rule out 
the use of VSL as an instrument for policy evaluation. The include a) problems with the 
practice of using a uniform VSL for all contexts – for instance a VSL that is measured in 
the context of work-related risks may not be applicable to a context of diet-related risks 
to health; b) commonly used measurement approaches make it difficult to interpret the 
resulting risk-wage tradeoff function; and c) risk preferences are correlated with risk 
exposures leading to overstated VSLs.] 
A number of studies and meta-analyses have been published on VSLs (Viscusi 1993; 
Miller 2000). For the purposes of this study, we anchor VSLs to a central estimate of $6.1 
million in 2004 dollars as recommended by the U.S. Environmental Protection Agency 
after an extensive analysis of the theoretical and empirical literature (U.S. Environmental 
Protection Agency (USEPA) 2000). 
 
 
Relationship of VSL to GDP 
 
Since hedonic wage studies have not been conducted in most low-income countries, a 
method known as benefits-transfer has been used to translate VSL estimates developed in 
11   high- and middle-income countries to low-income countries. Benefits-transfer involves 
adjusting VSL estimates developed in other countries for income differentials between 
countries. There are disadvantages to using such a benefits-transfer method; the most 
important one being that individual preferences with respect to risk are influenced 
strongly by cultural factors and may be quite different in low-income countries. 
Moreover, differences in the extent of the availability and cost of health services are 
likely to influence wage-risk tradeoffs in these countries. 
The benefits-transfer methods used in this analysis rely on estimates developed by 
Viscusi and Aldy (Viscusi and Aldy 2003). Based on more than 60 studies of mortality-
risk premiums from 10 countries, they estimate an income elasticity of the value of a 
statistical life
5 of about 0.5 to 0.6, but their elasticity estimates are influenced downward 
by three extreme observations for India. Dropping these observations yields an elasticity 
of roughly one (Becker and Elias 2003) and is the value used in more recent studies 
(Becker, Philipson et al. 2003). Using the lower elasticity would yield implausibly high 
estimates of VSL in low-income countries.  
Using an income elasticity of VSL of one and starting from the U.S. VSL of $6.1 
million (associated with a U.S. real per capita GDP in 2004 of roughly $40,000), we can 
compute the VSL of India (with real per capita GDP in 2004 of $625) to be $94,721. This 




Data on TB incidence and mortality from 2006–2015 are derived from WHO 
epidemiological models (WHO 2006). These models project TB incidence (both total and 
HIV+ cases), prevalence, and mortality for the years 2004–2015 under three scenarios: 
No DOTS, Sustained DOTS, and Global Plan strategy. The 2004 data from this report 
                                                 
5 This refers to the percentage change in VSL for a one percent change in GDP. 
6 An alternative, although arbitrary approach, adopted by some authors is to assume that VSL is 100 times GDP per 
capita (Jamison, Sachs et al. 2001; WHO 2005). Since we assume an elasticity of VSL with respect to GDP of one 
(Becker and Elias 2003), our estimates of VSL are a direct multiple of GDP in the same ratio as for the United States 
and indicate a VSL to GDP ratio of roughly 150. 
 
12   (the most recent year available at the time of this study) provide a baseline indicating the 
proportion of TB cases, TB cases co-infected with HIV, and deaths allocated to each 
country within a region. Since Global Plan projections are only available by region and 
not by country, for each subsequent year (2005–2015) we allocate region-specific TB 
deaths to each country in the same proportion as in the baseline year of 2004. This 
overestimates TB deaths in countries where deaths are expected to decline at a faster rate 
than the rest of the region and underestimates deaths in countries where TB deaths in 
coming years are likely to grow more rapidly than the rest of the region.  
Since prevalence surveys are lacking in most countries, estimates of the number of TB 
cases in most countries are based on case-notification data. Estimates based on case-
notification data can be unreliable (Murray, Lopez et al. 2004), since case-notification 
rates can be poorly correlated with actual prevalence, as shown by one study from India 
where the majority of TB cases are treated in the private sector (Borgdorff, Nagelkerke et 
al. 2000). However, WHO projections do make use of data from prevalence surveys 
wherever they are available. Given the difficulties in determining prevalence in 
individual countries, WHO’s TB department has tended to rely more on forecasts of 
relative changes rather than on absolute numbers of cases and deaths. Typically, these 
forecasts are accompanied by multivariate uncertainty and sensitivity analyses (see Dye, 
Garnett et al. 1998 for instance) to provide a range on the estimates as discussed later in 
this section.  
 
Value of Statistical Life Year Calculations 
We estimated the economic burden of TB deaths under the three scenarios outlined 
above for the 22 countries with the highest burden of TB. Region-specific life 
expectancies were derived from the Disease Control Priorities Project (www.dcp2.org). 
We followed WHO methods in assuming that a person faces the same probability of 
death at each subsequent age as the existing population. This is equivalent to supposing 
13   that period life expectancy is identical to cohort life expectancy.
7 Based on studies from 
South Africa, the average age of death from TB is 40 (Statistics South Africa 2006), so 
years of life lost are calculated by region as life expectancy at 40. Life expectancy for TB 
patients co-infected with HIV was assumed to be 10 (Morgan and Whitworth 2001). 
World Bank data on GDP levels for 2004 and projected growth rates for 2006–2015 were 
used. 
The value of statistical life-years (VSLYs) represents annuitized, age-specific VSLs 
based on age-specific years of life expectancy and a three percent discount rate
8 as per 










where r  is the discount rate and L  is life expectancy at birth. VSLYs are calculated 
for the United States using U.S.-specific life-expectancy estimates. Constant VSLYs 
were calculated for the two Africa regions (high HIV cases and low HIV cases) and for 
each of the 22 high-burden TB countries relative to a U.S. baseline VSLY of $200,310 
and using an elasticity of VSL with respect to income of one and varied in a sensitivity 
analysis from 0.8 to 1.2.
9  
 
Full-Income GDP Growth Rate Calculations 
Baseline estimates of full-income growth rates were based on the assumption that 
these were consistent with a Sustained DOTS scenario. Starting from this baseline, we 
calculated the reduction in full-income growth if DOTS was not sustained at the 2005 
level and the increase in full-income growth associated with implementing the Global 
Plan. Life expectancy data are from the United Nations Statistical Database 
                                                 
7 This is a good approximation for interventions that have little effect on overall life expectancy or the 
cohort survival curve. It has the effect, however, of making every intervention appear less effective when 
overall mortality is high; effectiveness is inversely correlated with disease burden. 
8 The constant discount rate of 3% per year recommended by Gold and colleagues is routinely used in 
evaluating health interventions in the United States (Gold, Siegel et al. 1996).   
9 Although there is some intuitive appeal to the idea that each year of life should be worth the same, recent 
estimates of VSLs from labor-market hedonic studies indicate that VSLYs may vary with age (Aldy and 
Viscusi 2006). However, they disagree on the shape of the VSLY curves with respect to age.  




We used the Latin Hypercube Sampling (LHS) method to assess uncertainty 
surrounding the effect of each scenario in each region (McKay, Beckman et al. 1979), 
which has been used extensively by epidemiologists to evaluate a number of different 
models (Blower and Dowlatabadi 1994; Tanaka, Small et al. 2000; Currie, Williams et al. 
2003). Because each input parameter is treated as a separate random variable, LHS is an 
efficient sampling design for dealing with large numbers of input parameters and is 
significantly more efficient than simple random and fractional-stratified sampling designs 
(see Blower and Dowlatabadi 1994).
10  
We generated 100 samples of the model parameters for each region (as computed in 
the program Palisade @Risk), assuming that model parameters act independently and 
take values that are triangularly distributed between lower and upper limits and the point 
estimate (Table 3). This analysis of unpredictability allows for three sources of 
uncertainty: (1) in regional trajectories of the TB epidemic before implementation of the 
Global Plan; (2) in the epidemiological response to a combination of interventions, given 
our imperfect understanding of TB’s natural history; and (3) in whether the interventions 
will be carried out precisely as specified in the Global Plan scenarios described below. To 
account for variation of the third kind, we allowed for errors of ± 20 percent in the annual 
case detection rate and ± 10 percent in treatment success. Thus, for example, case-
detection ranges between 80 percent and 120 percent of the anticipated value in each year 
of implementation of the Global Plan. The elasticity of the VSLY with respect to GDP 
also was included. 
                                                 
10 In a standard Monte Carlo simulation, each input parameter is randomly selected from within a 
probability distribution function (pdf) for each simulation. In LHS, each parameter distribution is stratified 
into equiprobable intervals and each interval is sampled exactly once (without replacement). An input 
vector is then generated composed of the random samples of each of the input parameters for each 
simulation and each value of every parameter is only used once, which increases efficiency. 
15   Parameter estimates were run through our model, and sample results were used to 
provide 95 percent confidence intervals for our estimates. Ninety-five percent confidence 
intervals were computed for the 22 high-burden endemic countries and the Africa region. 
 
4. Results 
To calculate economic benefits, we first calculated the estimated number of deaths for 
each country from 2006–2015, which is presented in Table 4. Results for the economic 
benefits and costs of TB control for Sub-Saharan Africa are presented in Tables 5 and 6 
and for the 22 high-burden countries in tables 7 and 8. All estimates are in 2006 U.S. 
dollars and are based on a 10-year projection over the period 2006–2015 using a discount 
rate of 3 percent. Implementation costs, which are assumed to be paid for by expenditures 
raised from national tax revenues, for the Sustained DOTS and Global Plan strategies 
were obtained from the Stop TB program at the WHO. This imposes economic welfare 
losses because people or firms change their behavior to reduce the amount of tax they 
must pay. To reflect these welfare losses (also known as the marginal excess burden of 
taxation), the WHO cost estimates were scaled by a factor of 1.3 (Ballard, Shoven et al. 
1985; Browning 1987).
11  
We find that the economic burden of deaths associated with TB (including HIV co-
infection) in Sub-Saharan Africa is $519 billion (95% CI, $475–$563) when there is no 
DOTS coverage (Table 5). The corresponding estimate when HIV co-infections are 
excluded is $239 billion (95% CI, $210–$268). The economic benefit of sustaining 
DOTS in Sub-Saharan Africa at 2005 levels of coverage is estimated to be $129 billion 
(95% CI, $113–$146), of which approximately 75 percent of the benefit is in countries 
with a high HIV burden (Table 6a). The benefits of moving from No DOTS to the Global 
Plan strategy are even greater at $217 billion (95% CI, $200–$235). The economic cost 
of implementing Sustained DOTS in Sub-Saharan Africa is $12.24 billion, representing 
                                                 
11 Warlters and Auriol estimate the marginal cost of public funds to be 1.17 based on a sample of 38 
African countries (Warlters and Auriol 2005). However, we decided to use the 1.3 figure both to obtain a 
more conservative estimate of benefit-cost ratio, as well as to reflect that in many countries a significant 
proportion of national TB-control program budgets will be funded by external assistance from high-income 
countries.  
16   about a ten-fold difference between the economic benefits and costs. The economic cost 
for implementing the Global Plan strategy for Sub-Saharan Africa is $22.24 billion, and 
again the benefits exceed costs by a factor of ten. Incremental benefits of implementing 
the Global Plan strategy relative to maintaining DOTS coverage at 2005 levels are $88 
billion (95% CI, $83–$93), while the incremental cost is $10 billion. Excluding benefits 
associated with lowering deaths in HIV co-infected patients significantly reduces the 
benefits, especially in countries with a high prevalence of HIV, but the benefits of 
implementing the Global Plan strategy relative to No DOTS still exceed the cost by a 
significant margin (Table 6b and Figure 3).  
The economic burden of TB between 2006 and 2015 for the 22 high-burden countries 
is estimated to range from $3.33 billion (95% CI, $3.07–$3.58) for Zimbabwe to $1,175 
billion (95% CI, $1,074–$1,277) for China under the No DOTS scenario (Table 7). China 
alone accounts for more than a third of the overall economic burden in these countries, 
and India and China together account for more than half. Despite having more than a 
third of the TB deaths, high-burden countries in Sub-Saharan Africa only account for 
about a tenth of the burden. 
Sustaining DOTS at 2005 coverage levels in the 22 high-burden countries would result 
in an estimated economic gain of around $1.6 trillion (over the period 2006–2015), 
ranging from $0.74 billion (95% CI, $0.64–$0.84) in Zimbabwe to $748 billion (95% CI, 
$638–$857) in China. While countries with a significant TB burden accrue the majority 
of benefits, approximately one-seventh of the benefits of sustained-DOTS programs 
accrue to the high-burden countries in Africa. 
Benefit-cost ratios for each of the 22 high-burden countries are provided in Table 8 
and Figure 3. Thailand has a benefit-cost ratio of more than 500, which is significantly 
greater than other countries, due in part to the low cost of implementation, while the 
Russian Federation, despite a significant burden, has a very low ratio, due both to the 
high cost of implementation as well as a low predicted reduction in mortality attributed to 
DOTS. In high-burden countries in Africa, benefit-cost ratios are all positive, with only 
Zimbabwe and the Democratic Republic of the Congo having ratios below 10.  
17   The incremental benefit of moving from a strategy of No DOTS to the Global Plan is 
much greater than that of moving from Sustained DOTS to the Global Plan because much 
of the benefits of TB control are captured in moving from no DOTS to sustained DOTS. 
Due to the greater uncertainty surrounding implementation of the Global Plan relative to 
Sustained DOTS, in some countries, notably Indonesia, Vietnam, and the Philippines, the 
range of benefits may be quite large and not statistically different from zero. 
Nevertheless, for half the countries the estimated benefits could exceed the costs by more 
than a factor of 10, suggesting that there are significant economic benefits in reaching 
beyond 2005 DOTS-coverage levels to achieve Global Plan targets. 
Annual GDP growth rates are contrasted with annual full-income growth rates in 
Table 9. Since full-income growth rates incorporate benefits from increased longevity, 
they are greater than GDP growth rates in countries where life expectancy is increasing. 
Only in South Africa, where life expectancy is declining, are full-income growth rates 
lower than GDP growth rates. Implementation of either type of TB-control strategy 
(Sustained DOTS or Global Plan) does not make a significant difference to annual full-
income growth rates ─ differences are on the order of 0.002-0.015 percentage points.  
 
Uncertainty analysis 
Partial rank correlation coefficients (PRCCs) were calculated in the same manner as 
Blower and Dowlatabadi (1994) for input parameters sampled using the Latin hypercube 
scheme and the two outcome variables (deaths and economic burden). PRCCs help to 
determine the independent effects of each parameter on outcome variables, even when 
the parameters are correlated, and the relative importance of input variables in 
determining the imprecision of the result can be assessed by comparing PRCCs. 
Correlation coefficients are presented in Tables 10–12 (for the three scenarios for the 
Africa region).
12 We find that the fraction of infections leading to progressive primary 
disease was the most significant input parameter in evaluating the range of the result. 
Other parameters, including death rates, fraction of infected individuals susceptible to re-
                                                 
12 PRCCs also were calculated for high-HIV+ countries and low-HIV+ countries in the Africa region, as 
well as for other regions and countries, with similar results. 
18   infection, fraction of infections smear-positive, the natural recovery rate, the reactivation 




We estimate the economic burden of TB mortality and the economic benefits of 
reducing TB-related deaths for the WHO Africa region, separately by high-HIV and low-
HIV countries and individually for the 22 high-burden, TB-endemic countries in the 
world using a VSL-based full-income approach. Starting from the baseline economic 
burden of TB-related deaths with no DOTS, we estimate the economic benefit of moving 
to: 1) a Sustained DOTS scenario where DOTS coverage from 2006–2015 continues at 
2005 levels; and 2) a Global Plan scenario where DOTS coverage is expanded and a 
number of other initiatives are introduced to aggressively control TB worldwide. We also 
evaluate the benefits of moving from Sustained DOTS to the Global Plan scenario and 
compare these to the marginal costs of implementing the Global Plan strategy. 
One could make a case for any DOTS intervention where the benefits exceed costs (or 
the benefit-cost ratio exceeds one). For the 22 high-burden countries, we find that there 
are significant benefits to Sustained DOTS coverage or Global Plan coverage relative to a 
baseline of no DOTS and relatively more modest benefits for moving from Sustained 
DOTS to the Global Plan scenario. Since much of the benefit of DOTS already is being 
reaped by the current level of coverage, increasing coverage likely will see declining 
marginal benefits. Benefit-cost ratios of moving from No DOTS to Sustained DOTS are 
in the order of 10, while the benefit-cost ratios of moving from Sustained DOTS to the 
Global Plan scenario are relatively lower in the 22 high-burden countries. The benefits of 
Global Plan coverage exceed costs in high-burden countries in Africa and for the 
continent as a whole. 
Economic impact estimates under the full-income approach are sensitive to changes 
both in per capita GDP and life expectancy attributable to TB interventions. A higher per 
capita GDP (which translates to a higher VSLY) and a greater number of years of 
potential life lost, both have the effect of increasing the estimated economic burden of 
19   TB-related deaths. Although the change in life expectancy attributable to the sustained 
DOTS program or the Global Plan strategy, and therefore changes in full income growth 
rates, is fairly small (since TB only accounts for about two percent of all deaths in low- 
and middle-income countries), the small change is scaled by the value of life, which is a 
large number. With rapid economic growth in many TB-endemic countries, VSLYs are 
projected to be even greater in the future, accounting for the sizable estimates of 
economic benefits.  
Among the 22 high-burden countries, the economic impact of TB deaths and the 
benefits of TB control are greatest in China and India, where the combination of growing 
incomes and a relatively high number of TB deaths translates into a significant economic 
effect. Although the greatest number of TB deaths occurs in Africa, the economic benefit 
of either DOTS scenario in Africa is modest in comparison to Asia for two reasons. One, 
income-growth projections for Africa over the next 10 years are more modest than for 
Asia. Second, the benefits of TB treatment in Africa are curtailed by the large burden of 
HIV co-infection. Nevertheless, the economic burden of TB in Africa is significant and 
the benefits of both Sustained DOTS and the Global Plan strategies are large and exceed 
the costs by a wide margin. 
Even if benefits of TB control programs exceed costs, the ratio of benefits to costs 
may be used to prioritize programs in resource-constrained settings. Tables 12a and 12b 
show benefit-cost ratios for other interventions targeted at young adults and projects 
supported by the World Bank in non-health sectors. Our estimates of benefit-cost ratios 
indicate that even among projects where benefits exceed costs, TB control programs offer 
very high returns in terms of economic benefits. 
 
Caveats 
Our estimation of economic benefits depends critically on epidemiological projections 
of mortality reductions attributable to DOTS and to the value of a statistical life in low-
income countries.  Further work is needed to develop more reliable estimates of 
epidemiological impact on the one hand, and VSLs on the other hand.  There are 
20   alternative approaches to VSL, each of which has pros and cons. The results of this 
model-based study are interpretable only to the extent that the approach is valid. 
WHO’s projections are based largely on case notifications that depend on the extent to 
which TB is treated in the public sector and the quality of health reporting in individual 
countries. Since the precision of benefits evaluated depend both on the evaluation of the 
VSL in individual countries and on the precision of mortality projections provided by 
WHO, we have subjected these numbers to an extensive sensitivity analysis that suggests 
that even if WHO’s estimates overstate mortality reductions, the economic benefits of 
Sustained DOTS typically exceed the costs. Benefit-cost ratios of the Global Plan 
scenario exceed one relative to no DOTS, but the incremental benefit relative to 
Sustained DOTS is not statistically significant in a number of countries. 
In addition, there is considerable uncertainty about the effects of DOTS on the 
transmission and incidence of TB. As such, this paper illustrates a VSL-based approach 
to measuring the benefits and cost–benefit ratios of global TB control. A more precise 
assessment of benefits evaluated in this paper will depend on more complete assessments 
of the effects of DOTS on mortality, transmission, and incidence.  
One might argue that our full-income estimates overestimate the effect of TB because 
we have not adjusted VSLs for the specific socioeconomic groups where death from TB 
is most likely. TB is a disease of poverty in many countries where it is prevalent. 
Malnutrition and overcrowding create ideal conditions for transmission of infection from 
person to person, and the disease is concentrated not just in the poorer countries of the 
world but also in the more disadvantaged socioeconomic groups within these countries. 
The poor are at greater risk of unemployment than their wealthier counterparts, even 
when they are not infected with TB, potentially limiting the economic effect of the 
disease. However, the socioeconomic dynamics of TB may be changing in Africa, where 
the greatest increases in future burden are predicted. Because of the relatively high co-
infection rate with HIV/AIDS and the relatively high prevalence of HIV among urban 
Africans in higher socioeconomic groups, our estimates for Africa may not be greatly 
biased upwards.  
21   We have also not considered the behavioral responsiveness of patients to the 
availability of treatment.  Others, most notably Tomas Philipson and colleagues, have 
shown that individuals modify their risk taking in response to perceptions of disease risk 
(Geoffard and Philipson 1996; Philipson 1999).   However, in the case of TB, infection is 
almost always involuntary; people have to breathe, and they become infected when they 
inhale air that contains the TB bacteria, a risk that is higher in crowded living conditions 
among the poor. In general, exposure to the risk of infection is reduced with 
improvements in living standards, which is subject to socio-economic circumstances 
rather than changes in individual behavior. Therefore, the effects of behavioral changes 
on our estimates are likely to be minimal. 
Also our assessment of benefits errs on the conservative side in two respects. First, the 
morbidity-reduction benefits of either DOTS scenario are excluded in our calculations. 
Second, the averted deaths used in our calculations exclude any benefits that may arise 
from investment in R&D that form part of the costs of the Global Plan strategy. Any new 
tools, especially a new vaccine, which would have the biggest effect on deaths in the long 
term, will not be available within the 10-year horizon of the Global Plan and are excluded 
from our cost–benefit assessment. 
 
Economic Benefits and Costs of the Global Plan in Africa 
The annual cost of implementing the Global Plan in Africa is $2.6 billion, of which 
$2.13 billion is for countries with a high burden of HIV co-infection. Our results indicate 
that the benefits of implementing a Global Plan strategy exceed the costs by a wide 
margin (relative to the no-DOTS baseline) even if the benefits of expanded coverage on 
lowering deaths in individuals with HIV co-infection were to be ignored. When the 
benefits of TB control in HIV co-infected patients are included, the benefit-cost ratio of 
the Global Plan in Africa is roughly ten-to-one (relative to No DOTS) and nine-to-one 
(relative to Sustained DOTS). Although HIV does curtail the effect of DOTS programs 
by lowering the life expectancy of those receiving treatment, the Global Plan does appear 
to be welfare-improving (relative to Sustained DOTS) in African countries with high 
levels of HIV. 
22   Benefit-cost ratios of the Global Plan strategy relative to Sustained DOTS were 
unambiguously greater than one in only 12 of the 22 high-burden countries. These 
include all nine that are in Africa, and also Pakistan, Afghanistan, and Russia. These 
results highlight the large avertable burden of TB in Africa and the significant economic 
benefits of the Global Plan strategy, in spite of challenges such as slow economic growth 
and high HIV co-infection. 
Table 13 shows benefit-cost ratios for investments in youth in selected countries 
(Knowles 2003) and for selected development bank-supported investments (Gaag and 
Tan 1998). The benefit-cost ratios of the Global TB Plan compare favorably with those 
estimated for these investments.  Such comparisons must be interpreted with caution, 
given the methodological and data challenges noted elsewhere in this paper. In addition, 
there are practical issues that affect their use.  For example, Jack (2000) points out that 
the benefit-cost ratio of a program is irrelevant as long as it is greater than one, in which 
case the program should be implemented.  However, policymakers face the reality of 
resource constraints and cannot fund everything. While it is useful to take into account 
the relative benefits of potential investments in different programs, the decision criteria 
often are multiple.  Country investment decisions often result from analyses and 
negotiations about the relative emphasis to put on competing interests and programs.  
While this paper will contribute to broader discussions at the global and country levels, 
the full scope of comparisons and decisions is beyond its scope.   
  
6.   Conclusions 
We evaluated economic benefits associated with DOTS for the Sub-Saharan Africa 
region and for the 22 countries with the highest burden of TB. The Global Plan to Stop 
TB, which covers the period 2006–2015, projects TB cases, TB cases that are co-infected 
with HIV, and TB deaths under three scenarios: no DOTS, sustained DOTS, and the 
Global Plan to Stop TB. Here we estimate the economic benefit of moving from a 
baseline of no-DOTS to one of sustained DOTS or to the Global Plan strategy as well as 
of moving from sustained DOTS to the Global Plan scenario.  
23   Based on a full-income approach that values deaths using the VSL, we estimated the 
economic burden of TB deaths in Africa between 2006 and 2015 to be $519 billion (95% 
CI, $475–$563) in a scenario with no DOTS coverage anywhere. Of this figure, $418 
billion (95% CI, $386–$450) is attributable to the burden in countries with a high level of 
HIV co-infection and $101 billion (95% CI, $89–$114) to the burden in countries with a 
low level of HIV co-infection. The present discounted benefit of moving from no DOTS 
to the scenario of sustained DOTS at 2005 coverage levels is $129 billion (95 % CI, 
$113–$146) and to a Global Plan strategy (from no DOTS) is $218 billion (95% CI, 
$200–$235). In comparison, the costs of implementation are $12.2 billion for a sustained 
DOTS program and $22.2 billion for the Global Plan strategy. These estimates represent 
a ten to one ratio of benefits to costs for sustained DOTS coverage and roughly nine to 
one for Global Plan implementation in the Africa region, relative to the baseline of no 
DOTS. A similar benefit-cost ratio is estimated for the Global Plan relative to sustained 
DOTS. 
The discounted burden in the countries with the highest burden of TB when a no-
DOTS strategy is implemented between 2006 and 2015 is estimated to be more than $3 
trillion and ranges from $3.3 billion (95% CI, $3.07–$3.58) for Zimbabwe to $1,175 
billion (95% CI, $1,074–$1,277) for China. The discounted benefit of maintaining DOTS 
at the 2005 coverage levels or implementing the Global Plan strategy between 2006 and 
2015 for the 22 high-burden countries is more than $1.6 trillion and $1.9 trillion, 
respectively, relative to a no-DOTS strategy. Benefit-cost ratios for a sustained-DOTS 
scenario (relative to no DOTS) typically exceed those for moving from sustained DOTS 
to a Global Plan strategy, except in Afghanistan, Russia, and South Africa.  
A full-income approach based on changes in the GDP growth rates related to changes 
in life expectancy found that implementation of either type of TB-control strategy 
(sustained DOTS or Global Plan) does not make a significant difference to full-income 
growth rates ─ differences are on the order of 0.002–0.015 percentage points.  
Our estimation of economic benefits depends critically on epidemiological projections 
of mortality reductions attributable to DOTS and to the value of a statistical life in low-
income countries.  Further work is needed to develop more reliable estimates of 
24   epidemiological impact on the one hand, and VSLs on the other hand.  There are 
alternative approaches to VSL, each of which has pros and cons.  The results of this 
model-based study are interpretable only to the extent that the approach is valid. 
 
 
25   Appendix 1: Modeling the Effect of the Global Plan to Stop TB 
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Figure A.1. Flow diagram of the compartmental model for tuberculosis. Refer to 
equations below for a formal description of the model, and to Table 3 for definitions 
and values of parameters.  
 
The potential impact of scenarios 2 and 3, as compared with scenario 1, has been 
evaluated with a mathematical transmission model describing, as in previous models 
(Blower, McLean et al. 1995; Dye and Williams 2000; Dye and Espinal 2001), how the 
planned interventions can be expected to reduce TB incidence, prevalence, and death 
rates through time. The structure of the core TB model is based on literature describing 
the natural history of TB, and fitted quantitatively to data defining the course of TB 
epidemics in seven regions of the world (Dye, Scheele et al. 1999; Corbett, Watt et al. 
2003; World Health Organization 2007). The core model is sketched as a flow chart in 
Figure A.1. We previously have shown how models of this kind can replicate the 
26   observed effect of drug-treatment programs carried out from the 1950s onwards (Dye, 
Garnett et al. 1998).  
 
Written in difference equations, as programmed in Visual Basic and Microsoft Excel, the 
basic TB model is as shown below. For simplicity and transparency, these equations 
describing the core model exclude the complications of HIV co-infection and multidrug 
resistant (MDR)disease, though both are included in the full model used to carry out 
calculations for the Global Plan. We assume that homogeneously mixing individuals in a 
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Recovered from infectious TB: 
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Active non-infectious TB: 
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The model does not distinguish people by age and sex. Among uninfected (U) individuals 
who acquire M. tuberculosis infection from contagious individuals (I) at time-dependent 
27   rate λ[t] (= βI[t], usually called the “annual risk of infection”), fraction f develop 
progressive primary TB within one year of contact. By contrast, fraction 1-f move into 
the latent class (L), from which they breakdown relatively slowly (endogenous 
reactivation at rateν) to active disease. TB can arise from latent infection many years 
after the infection was acquired. However, the progression from latency to active disease 
can be accelerated by (exogenous) re-infection, provided re-infection overcomes the 
partial immunity (measured by proportion x) acquired from the primary infection.  
 
Active disease is either infectious pulmonary TB (I, arising in fraction s of cases), in 
which most patients have a positive-sputum smear on microscopic examination, or non-
infectious pulmonary or extrapulmonary TB (N, fraction 1-s). Patients with active TB 
have an elevated death rate, which is higher for infectious (μi) than for non-infectious 
disease (μn), and much higher than the mortality rate from all other causes (μ). These 
death rates are expressed in terms of survival (e.g. 1- μ) from one time step to the next, 
which allows us to assign different survival rates to patients in the same state but who 
have with different fates. The notation [t] and [t-1] represents the value of state variables 
at, respectively, the current and at the previous time step (1 year ago). 
 
Birth and death rates are assumed equal so the total population remains constant. A small 
proportion of human TB cases are caused by mycobacteria other than M. tuberculosis, 
especially M. bovis, but they are not relevant to this analysis. More important are the 
effects of HIV and MDR-TB, which are modeled as extensions of the above equations 
(not shown here, but see e.g., (Dye and Williams 2000). 
 
Before drugs became available to treat TB in the 1940s, a proportion of patients self-
cured. Self-cure is still a part of TB natural history and is represented in this model by ρ. 
Case-detection rates (δ) are different for DOTS (subscript D) and non-DOTS or other 
programs (subscript O). In general, the efficacy of drug treatment (cure, κ) is higher when 
administered in DOTS programs than elsewhere. Patients that are cured, either naturally 
or by drug treatment, move to the recovered class (Ri or Rn), where they are assumed to 
remain (i.e., this version of the model does not allow relapse). 
 
Parameter values used for this investigation are similar to those used in previous 
modeling analyses (Vynnycky and Fine 1997; Dye, Garnett et al. 1998; Lietman and 
Blower 2000; Young and Dye 2006), and are given in Table 3. To reconstruct the recent 
epidemiological history of TB in seven regions of the world (representing the whole 
world except the established market economies and central Europe), the model was fitted 
to WHO estimates for incidence, prevalence, and deaths from 1990 (the baseline for the 
Millennium Development Goals [MDG]) to 2003 (the latest data available at the time of 
writing the Global Plan). The fitting was carried out principally by adjusting parameters 
determining the contact rate (β) and the natural recovery rate (ρ). An example of the fit 
(for the Western Pacific Region) is illustrated in Figure A.2. 
 
The effect of control is determined by inputs set out in the seven regional plans, as 
described in Table 11 of Annex 1 to the Global Plan (Stop TB Partnership and World 
Health Organization 2006). Case detection and cure rates are based on, and extended 
28   from, data compiled in WHO’s annual reports on Global Tuberculosis Control (World 
Health Organization 2007). While the model calculates incidence, prevalence, and deaths, 


























Figure A.2. TB model fitted (white bars) to WHO estimates (black bars) of incidence, 
prevalence, and death rates per 100,000 population in the Western Pacific Region, 1990 
and 2003. Grey bars are the MDG target values for 2015 and the corresponding white 
bars for 2015 are the expected outcome of implementing the Global Plan (scenario 3). 
The third panel shows the standard errors on calculated death rates, as derived from 
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+Figure 2: Predicted trends of TB incidence under following scenarios; No DOTS; DOTS 
sustained at 2005 level; and implementation of Global Plan to Stop TB, 2006-15 (WHO 
2006) 
 




Table 1: Deaths in 22 high burden countries TB endemic countries, 2004 





Afghanistan 12,645  5  12,640 
Bangladesh 86,506  268  86,238 
Brazil 16,608  4,450  12,158 
Cambodia 13,804  2,484  11,320 
China 229,978  3,274  226,705 
DR Congo  68,506  36,317  32,189 
Ethiopia 91,501  27,085  64,416 
India 419,773  66,761  353,012 
Indonesia 119,376  3,479  115,897 
Kenya 77,554  58,047  19,507 
Mozambique 39,681  49,655  0 
Myanmar 9,798  1,582  8,217 
Nigeria 161,877  93,730  68,147 
Pakistan 71,795  607  71,188 
Philippines 43,797  214  43,583 
Russian Federation  34,144  2,902  31,242 
South Africa  54,512  73,739  0 
Thailand 15,877  3,856  12,021 
Uganda 42,267  34,824  7,443 
UR Tanzania  46,605  36,547  10,058 
Vietnam 21,524  1,994  19,530 
Zimbabwe 27,483  34,345  0 
Total 1,705,612  536,162  1,205,513 




38   Table 2: Three scenarios outlined by Global Plan 
 
 
No DOTS  This assumes that the strategy was never introduced in any region, 
so treatment would continue as it was pre-DOTS, with variable 
rates of case detection and typically lower rates of cure. This gives 
a baseline against which to compare acquired and future gains. 
Sustained DOTS  Sustaining DOTS implementation at 2005 level (no new 
activities). Case detection and treatment success rates increase 
until 2005, and then remain steady until 2015. 
Global Plan  Full implementation of the Global Plan to Stop TB 2006–2015 
(the Global Plan) including expansion of DOTS coverage, 
programs to address TB/HIV coinfection and multi-drug resistant 
TB, new TB diagnostics, drugs, and vaccines; and efforts in 
advocacy, communications, and social mobilization.  
 
 
Source: DOTS Expansion Working Group Strategic Plan 2006 – 2015 
whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.370_eng.pdf 
39   40   
Table 3. Values of key parameters in the TB model The three values given for each parameter specify the base and 
apex of a triangular distribution. Values of β and ρ, parameters that are varied to fit the model to WHO estimates, are 
for the Western Pacific Region. 






(low, point, high) 
Infectious contacts/person/yr  β  βh  9, 9.5, 10 
Reactivation rate/person/yr  ν  νh  0.0001, 0.000138, 0.0002 
Proportion infections leading to progressive primary disease  f fh  0.12, 0.15, 0.18 
Proportion active cases sm+  s sh  0.4, 0.45, 0.5 
Proportion infected persons Susceptible to reinfection  x xh  0.1, 0.35, 0.6 
Natural recovery rate from TB/patient/yr  ρ  ρh  0.08, 0.1, 0.12 
Non-TB death rate/person/yr  μ  μh  0.01, 0.015, 0.02 
TB (sm+) death rate/patient/yr  μi  μi h  0.1, 0.13, 0.16 
TB (sm-) death rate/patient/yr  μin  μin h  0.025, 0.05, 0.075 
Efficacy IPT for HIV+ (TST+)    eipt  0.3,0.4,0.5 
Efficacy ART+CPT    eart  0.3,0.4,0.5 
Efficacy CPT    ecpt  0.5,0.6,0.7 
Parameters eipt, eart and ecpt specify the efficacy of isoniazid preventive therapy for people with latent infection (IPT), antriretroviral 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Table 10: Partial Rank Correlation Coefficients 
Economic Burden No DOTS: All Africa 
Parameter  PRCC 
f  0.952*** 
x   0.753*** 
r  -0.655*** 
μi  -0.648*** 
s  0.578*** 
VSLY elasticity  -0.469*** 
νh  0.401*** 
μh  -0.36*** 
ecpt  0.318*** 
β  0.308*** 
μih  -0.303*** 
μ  -0.3** 
2012 Ts  0.221** 
2011 Ts  -0.192* 
μin  0.166* 
 
Table 11: Partial Rank Correlation Coefficients 
Economic Burden Sustained DOTS: All Africa 
Parameter PRCC 
f  0.921*** 
μi  -0.672*** 
x   0.595*** 
r  -0.588*** 
s  0.563*** 
VSLY elasticity  -0.482*** 
νh  0.423*** 
μh  -0.32*** 
β  0.312*** 
μih  -0.265** 
ecpt  0.257*** 
μ  -0.246** 
eart  0.184** 
2015 Ts  0.177* 
μin  0.172* 
 
 
Table 12: Partial Rank Correlation 
Coefficients 
Economic Burden Global Plan: All Africa 
Parameter  PRCC 
f  0.95*** 
x   0.72*** 
r  -0.677*** 
μi  -0.672*** 
s   0.558*** 
49   νh  0.452*** 
VSLY elasticity  -0.44*** 
β  0.337*** 
μ  -0.31*** 
ecpt  0.304*** 
2010 smear + case detection  -0.259** 
2008 smear + case detection  -0.246** 
μih  -0.244** 
μh  -0.237** 
2013 smear + case detection  -0.217* 
2011 Ts   -0.213* 
μin  0.188** 
 
50   Table 13: Estimated benefit-cost ratios of some other programs evaluated by the World 
Bank  
Table 13a. Estimated benefit-cost ratios of some investments in youth in selected countries 
Investment  Estimated benefit-cost ratio 
(assuming 5% annual 
discount rate)
Plausible ranges in 
estimated benefit-cost 
ratio
Scholarship program (Columbia)  3.31 2.77 to 25.63
Adult basic education and literacy 
program (Columbia) 
19.9 8.14 to 1,764
School-based repoductive health 
program to prevent HIV/AIDS 
(Honduras) 
0.493 0.102 to 4.59
Iron supplementation administered to 
secondary school children (low-income 
country) 
32.1 25.8 to 45.2
Tobacco tax (middle-income country)  11.34 6.96 to 38.56
Source: Knowles and Berman (2003) 
Table 13b. Benefit-cost ratios for selected development bank-supported investments 
Project (year) Benefit-cost  ratio
Hill Forest Development Project, Nepal 
(1983) 
1.18
Irrigation Systems Improvement Project, 
Philippines (1977) 
1.48
Livestock Development Project, 
Uruguay (1970) 
1.59
Livestock and Agricultural Development 
Project, Paraguay (1979) 
1.62
Cotton Processing and Marketing 
Project, Kenya (1979) 
1.80
Source: van der Gaag and Tan (1998) 
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